myoscience Named Winner of the 2014 Red Herring Top 100

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
myoscience Named Winner of the 2014 Red Herring Top 100 North America Award

REDWOOD CITY, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- California based myoscience, inc., makers of the revolutionary iovera° system for treatment of peripheral nerves, has been named a winner of the prestigious Red Herring 2014 Top 100 North America Award. As a winner, myoscience joins a short list that honors the year's most promising private companies. Starting from a field of over 3,000 candidates, myoscience was selected as a Top 100 winner by Red Herring.

Award winners were selected using a rigorous evaluation process that included both quantitative and qualitative criteria, such as financial performance, technological innovation and intellectual property, management quality, business model, customer footprint and market penetration.

Myoscience's groundbreaking iovera° treatment utilizes the body's natural response to cold to deliver immediate results for both therapeutic and aesthetic applications. The iovera° system is FDA cleared for the treatment of pain in the United States and is approved in the European Union and Canada for the treatment of wrinkles.

"In 2014, selecting the top 100 achievers was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from all the candidates across North America to the top 100 winners. We believe myoscience embodies the vision, drive and innovation that define a successful entrepreneurial venture. Myoscience should be proud of its accomplishment, as the competition was very strong."

"We are proud of our team, grateful to our investors, and very honored to have been selected for this highly coveted distinction," said myoscience CEO Clint Carnell. "This selection further validates the hard-work and dedication of our team in bringing this remarkable platform technology to patients around the world."

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com .

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.   MKT-0250 REV A

1600 Seaport Blvd., Ste. 450 / Redwood City, CA Tel: 650.474.2600 / iovera.com MEDIA RELATIONS Jay Patel /

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 163

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 260

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 220

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 210

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 173

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 244

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 164

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 233

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading

Top 5 Most Recently Viewed Articles

AOB Pharma's Latest Breakthrough in Atopic Dermatitis Treatment

Updated Category News Views 152

AOB Pharma Advances Atopic Dermatitis Treatment with B244 AOB Pharma, known for its innovative approach to inflammatory skin conditions, is excited to announce significant progress regarding its lead product, B244. This first-in-class topical live biotherapeutic is aimed at treating mild to moderate atopic dermatitis, commonly affecting children, adolescents, and adults...

Continue Reading
Prospects of Hello Group Inc's Upcoming Earnings Report

Updated Category News Views 136

Understanding Hello Group Inc's Earnings Outlook Hello Group Inc (NASDAQ: MOMO) is on the verge of releasing its quarterly earnings report. As anticipation builds, it's pivotal for investors to grasp the key aspects of the upcoming announcement. Projected Earnings and Investor Sentiment Analysts project that Hello Group will announce an earnings per share (EPS) of $0.17....

Continue Reading
Drax Group's Economic Impact: $1 Billion Boost to Canada

Updated Category News Views 64

Drax Group's Economic Influence in Canada A recent study highlights the significant impact that Drax Group has on the Canadian economy, showing an astonishing $1 billion contribution. Conducted by a team of independent experts, this analysis emphasizes how Drax's wood pellet production is creating over 3,000 jobs throughout the country, driving growth in renewable energy...

Continue Reading
Youth Track and Field Championships Set to Inspire Athletes

Updated Category News Views 259

A Spectacular Event for Young Athletes The Royal Canadian Legion National Youth Track and Field Championships is a celebrated event in Canada. This gathering will bring together over 1000 young athletes from coast to coast, marking a momentous occasion for competitors aged under 16 and under 18. This year promises to be extraordinary as these young talents showcase their...

Continue Reading
DexCom, Inc. Investors Urged to Act Quickly Before Class Action Deadline

Updated Category News Views 186

DexCom, Inc. Class Action Lawsuit Insights Attention to all investors of DexCom, Inc. (NASDAQ: DXCM): a notable opportunity to join a critical class action lawsuit is upon us. If you purchased DexCom securities during the specified time frame, your potential for seeking compensation is on the line. This informative guide covers everything you need to know about the...

Continue Reading